Volume 27, Issue 3 (7-2024)
J Arak Uni Med Sci 2024, 27(3): 131-136 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Najafi A, Momeni-Moghaddam M A, salarbashi D, Amini Beidokhti N, Rahmani M, Khorasani M. Association of Interleukin-1 Antagonist Receptor Gene Polymorphism (rs2236663) and Type 2 Diabetes in Gonabad city. J Arak Uni Med Sci 2024; 27 (3) :131-136
URL: http://jams.arakmu.ac.ir/article-1-7626-en.html
URL: http://jams.arakmu.ac.ir/article-1-7626-en.html
Amir Najafi1 
, Mohammad Amin Momeni-Moghaddam2 , Davoud Salarbashi2 , Narges Amini Beidokhti3 , Marziye Rahmani4 , Milad Khorasani5 
, Mohammad Amin Momeni-Moghaddam2 , Davoud Salarbashi2 , Narges Amini Beidokhti3 , Marziye Rahmani4 , Milad Khorasani5
1- Medical Student, Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
2- Department of Nutrition and Biochemistry, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
3- Medical Laboratory Student, Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
4- Medical student, Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
5- Healthy Ageing Research Centre, Department of Biochemistry and Nutrition, Neyshabur University of Medical Sciences, Neyshabur, Iran ,miladkh24@yahoo.com
2- Department of Nutrition and Biochemistry, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
3- Medical Laboratory Student, Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
4- Medical student, Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran
5- Healthy Ageing Research Centre, Department of Biochemistry and Nutrition, Neyshabur University of Medical Sciences, Neyshabur, Iran ,
Abstract: (655 Views)
Introduction: Type 2 diabetes is a non-communicable disease that imposes a significant financial burden on the healthcare system each year. Numerous studies have demonstrated the involvement of inflammatory factors in the initiation and progression of this condition. The primary goal of this study is to compare the polymorphism of the interleukin 1 receptor antagonist gene among individuals with type 2 diabetes and those in the control group.
Methods: Following approval from the Ethics Committee of Gonabad University of Medical Sciences, blood samples were collected from 100 participants at Bohlool Hospital in Gonabad. These individuals were categorized into two groups: cases (individuals with type 2 diabetes) and controls (healthy individuals). DNA extraction was carried out using the salting out method. To examine the polymorphism, the specific segment was initially amplified through PCR with designated primers and then identified via gel electrophoresis. The data were analyzed using subjected to the Chi-square test at a significance level below 5%.
Results: Findings from the polymorphism analysis revealed a notable contrast in the genotype 2/1 (P = 0.001) and 2/2 (P = 0.004) within the case group when compared to the healthy participants. Specifically, individuals with genotype 2/1 exhibited a heightened risk of developing type 2 diabetes by up to 15 times.
Conclusions: Within the examined population, the polymorphism of the interleukin 1 receptor antagonist gene substantially influenced the predisposition to type 2 diabetes, amplifying the likelihood of developing this ailment. Individuals harboring allele 2 are at an increased susceptibility to type 2 diabetes.
Methods: Following approval from the Ethics Committee of Gonabad University of Medical Sciences, blood samples were collected from 100 participants at Bohlool Hospital in Gonabad. These individuals were categorized into two groups: cases (individuals with type 2 diabetes) and controls (healthy individuals). DNA extraction was carried out using the salting out method. To examine the polymorphism, the specific segment was initially amplified through PCR with designated primers and then identified via gel electrophoresis. The data were analyzed using subjected to the Chi-square test at a significance level below 5%.
Results: Findings from the polymorphism analysis revealed a notable contrast in the genotype 2/1 (P = 0.001) and 2/2 (P = 0.004) within the case group when compared to the healthy participants. Specifically, individuals with genotype 2/1 exhibited a heightened risk of developing type 2 diabetes by up to 15 times.
Conclusions: Within the examined population, the polymorphism of the interleukin 1 receptor antagonist gene substantially influenced the predisposition to type 2 diabetes, amplifying the likelihood of developing this ailment. Individuals harboring allele 2 are at an increased susceptibility to type 2 diabetes.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2024/01/29 | Accepted: 2024/08/13
Received: 2024/01/29 | Accepted: 2024/08/13
References
1. Kaur A, Thakur S, Deswal G, Chopra B, Dhingra AK, Guarve K, et al. In silico docking based screening of constituents from Persian shallot as modulators of human glucokinase. J Diabetes Metab Disord. 2023;22(1):547-70. pmid: 37255832 doi: 10.1007/s40200-022-01176-z
2. Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, Dalton BE, Duprey J, Cruz JA, Hagins H. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023. DOI: doi: 10.1016/S0140-6736(23)01301-6
3. Momeni-Moghaddam MA, Chahkandi H, Amini Beidokhti N, Rahmani M, Salarbashi D, Khorasani M. Angiotensin-converting enzyme I/D gene polymorphism and risk of type 2 diabetes mellitus in Iranian individuals. Nucleosides Nucleotides Nucleic Acids. 2024:1-10. pmid: 38651253 doi: 10.1080/15257770.2024.2343904
4. Moradi Y, Baradaran HR, Djalalinia S, Chinekesh A, Khamseh ME, Dastoorpoor M, et al. Complications of type 2 diabetes in Iranian population: An updated systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(3):2300-12. pmid: 31235172 doi: 10.1016/j.dsx.2019.05.018
5. Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549-64. pmid: 32437299 doi: 10.1161/CIRCRESAHA.119.315896
6. Nasrollahzadeh R, Momeni Moghaddam MA, Salarbashi D, Khorasani M. Association between IL-4 Gene VNTR Polymorphism and Type 2 Diabetes. Health Res Develop. 2023;1(2):1-8. doi: 10.61186/jhrd.1.2.1
7. Sjöholm Å, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006;22(1):4-10. pmid: 15991254 doi: 10.1002/dmrr.568
8. Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol. 2019;18(1):72. pmid: 31164120 doi: 10.1186/s12933-019-0870-9
9. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity. 2010;43(4):255-63. pmid: 19845478 doi: 10.3109/08916930903305641
10. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes care. 2008;31(Suppl 2):S161-S164. pmid: 18227479 doi: 10.2337/dc08-s243
11. Frühbeck G, Catalán V, Ramírez B, Valentí V, Becerril S, Rodríguez A, et al. Serum levels of IL-1 RA increase with obesity and type 2 diabetes in relation to adipose tissue dysfunction and are reduced after bariatric surgery in parallel to adiposity. J Inflamm Res. 2022;15:1331-45. pmid: 35237063 doi: 10.2147/JIR.S354095
12. Ibrahimi R, Ibrahimi M, Jamalzei B, Akbari ME, Navari M, Moossavi M, et al. Association between interleukin-1 receptor antagonist (IL-1ra) VNTR, gene polymorphism and breast cancer susceptibility in Iranian population: Experimental and web-based analysis. Int J Immunogenet. 2022;49(4):254-9. pmid: 35838420 doi: 10.1111/iji.12584
13. Ibrahimi M, Moossavi M, Mojarad EN, Musavi M, Mohammadoo-Khorasani M, Shahsavari Z. Positive correlation between interleukin-1 receptor antagonist gene 86bp VNTR polymorphism and colorectal cancer susceptibility: a case-control study. Immunol Res. 2019;67(1):151-6. pmid: 30382562 doi: 10.1007/s12026-018-9034-3
14. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110(25):3842-8. pmid: 15596567 doi: 10.1161/01.CIR.0000150391.38660.9B
15. Ghanbari M, Maragheh SM, Aghazadeh A, Mehrjuyan SR, Hussen BM, Shadbad MA, et al. Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies. Int Immunopharmacol. 2021;96:107765. pmid: 34015596 doi: 10.1016/j.intimp.2021.107765
16. Liao X, Xiao Y, Elbelt U, Weylandt KH, Li K, Deng J, Zeng N, Xue C. Association of interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms and plasma levels with diabetic nephropathy. Biomed Res Int. 2022;9661823. pmid: 35663044 doi: 10.1155/2022/9661823
17. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta. 2012;413(15-16):1163-70. pmid: 22521751 doi: 10.1016/j.cca.2012.03.021
18. Abed NT, Ramadan IA, Mohammed SA, El-Shanawany EM. Genetic polymorphism of interleukin-1 receptor antagonist in Type 1 diabetic children. Pediatr Res. 2022;91(6):1536-41. pmid: 34002010 doi: 10.1038/s41390-021-01569-5
19. Mohammadoo-Khorasani M, Salimi S, Tabatabai E, Sandoughi M, Zakeri Z. Association of interleukin-1 receptor antagonist gene 86bp VNTR polymorphism with systemic lupus erythematosus in south east of Iran. Zahedan J Res Med Sci. 2013;16(12): e23400.
20. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ, Duff GW. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet. 1996;97(6):723-6. pmid: 8641687 doi: 10.1007/BF02346180
21. Klashami ZN, Mostafavi A, Roudbordeh MG, Abbasi A, Ebrahimi P, Asadi M, et al. Investigating the relationship between the VNTR variant of the interleukin-1 receptor antagonist gene and coronary in-stent restenosis. Mol Biol Rep. 2023;50(10):8575-87 pmid: 37644369 doi: 10.1007/s11033-023-08759-w
22. Pehlivan S, Oyaci Y, Tuncel FC, Aytac HM. Interleukin-1 receptor antagonist (IL-1RA) and interleukin-4 (IL-4) variable number of tandem repeat polymorphisms in schizophrenia and bipolar disorder: an association study in Turkish population. Egypt J Med Hum Genet. 2022;23(1):127. doi: 10.1186/s43042-022-00341-6
23. Miller CD, Phillips LS, Tate MK, Porwoll JM, Rossman SD, Cronmiller N, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care. 2000;23(4):444-8. pmid: 10857932 doi: 10.2337/diacare.23.4.444
24. Burke SJ, Batdorf HM, Burk DH, Martin TM, Mendoza T, Stadler K, et al. Pancreatic deletion of the interleukin-1 receptor disrupts whole body glucose homeostasis and promotes islet β-cell de-differentiation. Mol Metab. 2018;14:95-107. pmid: 29914854 doi: 10.1016/j.molmet.2018.06.003
25. Herder C, Brunner EJ, Rathmann W, Strassburger K, TABak AG, Schloot NC, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2009;32(3):421-3. pmid: 19073760 doi: 10.2337/dc08-1161
26. Poitout V, Robertson RP. Minireview: secondary β-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143(2):339-42. pmid: 11796484 doi: 10.1210/endo.143.2.8623
27. Rhodes CJ. Type 2 diabetes-a matter of ß-cell life and death? Science. 2005, 307(5708):380-4. pmid: 15662003 doi: 10.1126/science.1104345
28. Velikova TV, Kabakchieva PP, Assyov YS, Georgiev TА. Targeting inflammatory cytokines to improve type 2 diabetes control. Biomed Res Int. 2021;7297419. pmid: 34557550 doi: 10.1155/2021/7297419
29. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin 1-receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32(9):1663-8. pmid: 19542207 doi: 10.2337/dc09-0533
30. Oldfield L, Evans A, Rao RG, Jenkinson C, Purewal T, Psarelli EE, et al. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine. 2022;75:103802. pmid: 34990893 doi: 10.1016/j.ebiom.2021.103802
31. Ruotsalainen E, Salmenniemi U, Vauhkonen I, Pihlajamäki J, Punnonen K, Kainulainen S, Laakso M. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care. 2006;29(12):2714-20. pmid: 17130210 doi: 10.2337/dc06-0147
32. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta. 2012;413(15-16):1163-70. pmid: 22521751 doi: 10.1016/j.cca.2012.03.021
33. Lee SH, Ihm CG, Sohn SD, Lee TW, Kim MJ, Koh G, et al: Polymorphisms in Interleukin-1β and Interleukin-1 Receptor Antagonist Genes Are Associated with Kidney Failure in Korean Patients with Type 2 Diabetes mellitus. Am J Nephrol. 2004;24(4):410-4. pmid: 15286433 doi: 10.1159/000080044
34. Jiao J, Wang Z, Guo Y, Liu J, Huang X, Ni X, et al. Association between IL-1B (-511)/IL-1RN (VNTR) polymorphisms and type 2 diabetes: a systematic review and meta-analysis. PeerJ. 2021;9:e12384. pmid: 34754627 doi: 10.7717/peerj.12384
35. Blakemore AI, Cox A, Gonzalez A-M, Maskill JK, Hughes ME, Wilson RM, et al. Interleukin-1 receptor antagonist allele (ILIRN* 2) associated with nephropathy in diabetes mellitus. Hum Genet. 1996;97(3):369-74. pmid: 8786086 doi: 10.1007/BF02185776
36. Freedman BI, Yu H, Spray BJ, Rich SS, Rothschild CB, Bowden DW. Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans. Kidney Int. 1997;51(3):819-25. pmid: 9067916 doi: 10.1038/ki.1997.115
37. Bensen JT, Langefeld CD, Hawkins GA, Green LE, Mychaleckyj JC, Brewer CS, et al. Nucleotide variation, haplotype structure, and association with end-stage renal disease of the human interleukin-1 gene cluster. Genomics. 2003;82(2):194-217. pmid: 12837270 doi: 10.1016/s0888-7543(03)00123-x
38. Luotola K, Pietilä A, Zeller T, Moilanen L, Kähönen M, Nieminen MS, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med. 2011;269(3):322-32. pmid: 21205020 doi: 10.1111/j.1365-2796.2010.02294.x
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
